Keyword: Sangamo BioSciences
After bagging a new R&D leader at the start of the year, Sangamo has hired a new chief medical officer for its gene editing and therapy work.
The update adds to the impression that the gene therapy is a threat to assets including BioMarin’s valrox and Spark Therapeutics’ SPK-8011.
Sangamo saw its stock on the up this morning after it posted updates to a series of its trials using a new form of gene editing and cell therapies.
The treatment failed to have the hoped-for effects on patients with the rare disease MPS II, causing investors to drive Sangamo’s stock down 30%.
The hire gives Sangamo an R&D chief with deep immuno-oncology experience as it works to advance its pipeline.
In his new role as chief scientific officer, Gary Lee will head up the expansion of Senti’s synthetic biology platform.
Winson Tang is accused of telling a friend about a 2014 agreement between Sangamo and Biogen before the news became public.
The €72 million takeover positions Sangamo to move a CAR-carrying regulatory T cell therapy into testing in solid organ transplant patients next year.
Human Longevity CFO/COO departs after scandal; Sangamo loses another top executive; McCann Health fires chief creative for conduct violation and more.
Another study warns of potential toxicity with CRISPR gene-editing, and gives investors in biotechs developing the technology the jitters.